WEBULL
News
MBX
28.67
+3.50%
0.97
A Look at MBX Biosciences (MBX) Valuation After Goldman Sachs’ Bearish Initiation of Coverage
Simply Wall St · 8h ago
Earnings Scheduled For December 18, 2025
Benzinga · 1d ago
MBX Biosciences to Present at J.P. Morgan Healthcare Conference
Reuters · 4d ago
Weekly Report: what happened at MBX last week (1208-1212)?
Weekly Report · 4d ago
MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains
Seeking Alpha · 12/10 17:54
Weekly Report: what happened at MBX last week (1201-1205)?
Weekly Report · 12/08 09:51
Do MBX Biosciences’ Phase 2 Win and Cash Raise Strengthen Its Platform Story or Expose Limits (MBX)?
Simply Wall St · 12/05 17:27
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA)
TipRanks · 12/05 13:10
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX)
TipRanks · 12/05 13:00
MBX Biosciences, Inc. (MBX) Gets a Buy from Guggenheim
TipRanks · 12/05 12:45
Midday Fly By: Meta to slash metaverse spending, Salesforce posts Q3 beat
TipRanks · 12/04 17:01
Morning Movers: Genesco, Build-A-Bear slide following quarterly results
TipRanks · 12/04 13:55
MBX Biosciences Price Target Announced at $18.00/Share by Goldman Sachs
Dow Jones · 12/04 12:57
MBX Biosciences drops 4% in premarket trading after Goldman initiates with Sell
TipRanks · 12/04 12:50
Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18
Benzinga · 12/04 12:47
MBX Biosciences initiated with a Sell at Goldman Sachs
TipRanks · 12/04 11:55
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%
NASDAQ · 12/01 14:55
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus
NASDAQ · 12/01 14:20
Weekly Report: what happened at MBX last week (1124-1128)?
Weekly Report · 12/01 09:48
A Look at MBX Biosciences (MBX) Valuation Following Phase 2 Results and Public Offering Plans
Simply Wall St · 11/25 04:35
More
Webull provides a variety of real-time MBX stock news. You can receive the latest news about MBX Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.